D&MD s Drug Targets from Genomics: Evolving Tools for Discovery seeks to examine the roles omic technologies play in pharma R&D, to asses their value to pharma, and to predict their future role and value.
This Report analyzes current and projected revenues from sales of omic technology-based products (reagents and consumables), which in 2004 totaled nearly $1.5 billion. Revenues are projected to increase to $2.3 billion by 2009. Also provided is a breakdown of revenues into transcriptomic, proteomic, metabolomic, and genotyping categories.
View Cart
